Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International randomized phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in children and adults with refractory or relapsed rhabdomyosarcoma.

Next Previous
Search
Trial Profile

International randomized phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in children and adults with refractory or relapsed rhabdomyosarcoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temozolomide (Primary) ; Irinotecan; Vincristine
  • Indications Rhabdomyosarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Sep 2019 Status changed from active, no longer recruiting to completed.
    • 02 Aug 2019 This trial has been completed in France, according to European Clinical Trials Database(2019-05-03)
    • 04 Jun 2019 Primary endpoint (centrally reviewed objective response rate (ORR) after 2 cycles) has not been met as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top